Last checked at 25 May 2018 07:00
| 25 May 2018 |
Futura Medical plc
("Futura" or "the Company")
Application for Block Listing
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology today announces that an application has been made to the London Stock Exchange to extend its block listings of securities by a total of 1,190,000 ordinary shares of 0.2 pence each (the "New Ordinary Shares") which may arise pursuant to the exercise of options under the Company's Unapproved Share Option Scheme and its EMI Share Option Scheme.
It is expected that admission will become effective on or around 30 May 2018 ("Admission"). Following Admission, the Company will notify its Schedule Six (block listing interim review) update for the period from 25 November 2017 to 30 May 2018.
Any New Ordinary Shares issued will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.
For further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
Email to: james.barder@futuramedical.com | www.futuramedical.com |
N+1 Singer (Nominated Adviser and Broker) |
|
Aubrey Powell / Liz Yong Corporate Finance
| Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: |
|
Buchanan |
|
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com